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Abstract
Background: Treatment of patients with knee osteoarthritis is challenging. Unloader braces have been developed
with various success. Unloader One® Knee Brace is light, easily-fitted and shown to be effective by the unloading of
the affected compartment. The aim of the study was to assess the clinical outcome of the brace vs. a placebo on
patients with knee osteoarthritis.
Methods: Initially 150 patients were randomized to receive either the Unloader brace or a control placebo group
look-alike brace where the active strips had been removed. The patients were followed up at 6,12,26 and 52 weeks
with Knee Society Score (KSS) and Knee injury and Osteoarthritis Outcome Score (KOOS). The reason for dropout
was recorded.
Results: A total of 149 patients were included, 74 in the study and 75 in the control group. The mean age was 59.6
vs. 60.2, BMI was 27.5 vs. 26.9, 37% vs. 44% were women in the study vs. control group. Both groups showed
improvement in KSS over 52 weeks, with the study group showing higher improvement in mean scores. KSS
increased from 64.3 to 84.0 for the study group and from 64.0 to 74.6 for the control group (p = 0.009). The
study group improved in KSS function from 67.0 to 78.6 (p < 0.001) and KOOS for knee related symptoms
increased/improved from 64.3 to 72.4 (p < 0.001). Activity of daily living increased/improved from 65.3 to 75.2
and Sports/Recreation from 24.6 to 40.2 (p > 0.001) whereas the control group did not show significant
improvements in any of the scores. The dropout was higher in the control group, 40 vs. 25.
Conclusions: The brace seems to be more effective and better tolerated than the placebo.
Trial registration: The trial was retrospectively registered with ClinicalTrials.gov (NCT03454776) on March 6th 2018.
Background
Osteoarthritis (OA) is a progressive degenerative joint
disease that involves damage to the joint cartilage and
changes in the subchondral bone and connective tissue
of the joints [1]. Risk factors include obesity, occupation,
trauma, excess joint load and hereditary factors [1, 2].
As populations age and obesity increases the burden of
knee OA is rising [3]. No cure exists for OA and all
current treatments focus on symptom alleviation. Even
though there are numerous well-documented treatments
available, the treatment of OA of the knee in younger
patients as well as older patients with mild to moderate
pain still poses a challenge. The current consensus is
that non-operative treatment is recommended before
surgery, with a combination of pharmacological treat-
ment and non-pharmacological modalities, such as pa-
tient education, physical therapy, weight loss, walking
aids and braces [4]. In unicompartmental knee OA with
valgus/varus misalignment, unloading of the affected
compartment has shown to be effective in biomechanical
studies [5]. Knee braces unloading the diseased compart-
ment have been shown to be effective in several studies
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and are included in many guidelines for the treatment of
symptomatic knee OA [6–9]. Many of these studies are
limited by having few test subjects or short follow up
times. Some studies have failed to show benefit of braces
compared to other treatments [10] and a Cochrane re-
view [11] published 2015 states that evidence for the use
of braces is inconclusive. In this review osteoarthritis of
different types and severities are analyzed. In this study
only patients with mild to moderate osteoarthritis (Ahl-
bäck grade I-II) were included, as we believe this to be
the target group for this type of treatment. The aim of
this study was to assess the one-year clinical effect of an
unloader knee brace compared to a placebo, evaluate
compliance and reasons for discontinuing treatment.
Methods
This study was a randomized placebo controlled study
in patients with mild to moderate knee OA. All patients
included were initially treated in primary care settings,
with patient education, physical therapy and analgesic
use. Patients visiting our outpatient clinic who met the
inclusion criteria were asked to join the study. Some pa-
tients were recruited after responding to advertisements
in local newspapers and social media. The first patient
was included in April 2012 and the last in August 2014.
The follow up time was 12 months. An orthopedic sur-
geon evaluated symptoms and radiographic evidence be-
fore inclusion in the study. All patients between 30 to
70 years of age, with knee pain for more than three
months, with arthroscopic or radiographic evidence of
knee OA (Allbäck or Kellgren-Lawrence grade 1–2)
[12], and with BMI < 35 were eligible for the study. Pa-
tients who had prior major surgery to the same knee, a
history of stroke, neurological or psychiatric problems,
patients using opioids or steroids, as well as patients
with rheumatoid arthritis, immunological depression or
other severe medical problems were excluded.
150 patients were randomized to either a study group
or a control group and followed for one year. The study
group received an Unloader One® knee brace (Ossur,
Iceland, Fig. 1). The Unloader One uses two Dynamic
Force Straps (DFS) to impart a force against the lateral
side of the knee as the knee extends. The purpose of this
force is to reduce the load in the medial knee compart-
ment. The control group received an Unloader One
brace, with the DFS removed. The purpose was to create
a device that looked like the Unloader One® brace but
without its functionality.
Information about age, gender, height, weight and occu-
pation were collected. A study nurse randomized the pa-
tients to either of the two groups. An orthopedic
technician fitted all the braces and the researchers collect-
ing all the data were blinded. All patients were graded by a
physician for Knee Society Score (KSS) [13] and answered
self-administered questionnaires; Knee injury and Osteo-
arthritis Outcome Score (KOOS) [14] before applying the
brace at baseline and after 6,12,26 and 52 weeks. The KSS
Fig. 1 Unloader One® brace, Ossur, Iceland
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is a mixed outcome score, which is both objective and sub-
jective. The KOOS is a self-administered patient reported
outcome measurement questionnaire divided into five
subcategories of pain, knee related symptoms, activities of
daily living (ADL), sport and recreation (S&R) and quality
of life (QoL). When answering the KOOS, patients are
asked to consider their experience over the previous week.
The results from both of these measurements are pre-
sented on a best-to-worst scale from 100 to 0. The KSS
Score and function as well as the five subgroups of KOOS
were determined as primary endpoints of the study. The
reasons for dropout were documented, as well as analgesic
use, frequency of doctor visits, absence from work and
changes in employment status, which were considered
secondary endpoints. Initially an evaluation of the cost of
treatment and economic aspects were included as a sec-
ondary outcome, but were later discarded due to lack of
data. All the patients from the control group that dropped
out of the study due to ineffectiveness or mechanical prob-
lems were informed that they had a placebo brace and
were offered to try out the original brace as one of the
treatment options available to them. The treatment is not
considered harmful but the placebo treatment may cause
delay in treatment.
The data was analyzed and 95% confidence interval
was calculated using a mixed model repeated measures
analysis of variance. This method uses all available infor-
mation and includes justifications for baseline imbalance
with stratification of randomized confounding factors.
An independent statistician analyzed all data presented.
Statistical analysis was performed with STATA (Stata-
Corp. 2015. Stata Statistical Software: Release 14. College
Station, TX: StataCorp LP.) Power and sample size cal-
culation was done with the PS: Power and Sample Size
Calculation program by William D. Dupont and Walton
D. Plummer, Jr. version 3,0. 2009 [15].
The results of data collected from KSS and KOOS are
presented as estimated marginal mean difference at 6,
12, 24 and 52 weeks and 95% confidence interval.
Results
In total 149 patients answered questionnaires at baseline,
74 in the study group and 75 in the control group. All
patients had unilateral medial OA, 80 in the left knee
and 68 in the right knee. After 52 weeks 85 patients
were still participating in the study, 50 in the study
group and 35 in the control group. The reasons for
dropout are shown in the flowchart below (Fig. 2). The
main reasons for dropout were mechanical problems
while using the brace. These problems include problems
using the brace while working, sliding off, rubbing, feel-
ing of instability and some patients found the brace to
cumbersome to use. Nine patients underwent surgery
before the study time was completed, 5 in the study
group (3 total knee replacements, 1 total hip replace-
ment, 1 high tibia osteotomy) and 4 in the control group
Fig. 2 Participant flow. KSS and KOOS show how many participants were evaluated for KSS or turned in KOOS questionnaires at that follow-up
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(2 total knee replacements, 1 high tibia osteotomy and 1
spinal surgery). Some patients chose to discontinue the
study due to work or lack of time, but continued to use
the unloader brace, and are listed under logistics. Three
patients reported silicone reaction or allergy as one of
the reason for stop using the brace. One patient was in-
cluded and given a subject number, but for reasons un-
known to us, his data is missing and no record of him
being fitted with a brace or called for evaluation. This
explains why there are only 149 patients in the study.
Demographics
The baseline demographic and clinical characteristics
are shown in Table 1.
Primary endpoints
KSS
Both groups showed an initial decline in KSS at six
weeks indicating worsening of symptoms, followed by
increase at three months indicating fewer symptoms,
which continued until the end of study at twelve
months. At six months the study group showed more
improvements than the control group and the difference
had increased even further at twelve months from 64.3
(95% CI 60.6–68.0) to 84.0 (95% CI 79.5–88.5) compared
to 64.0 (95% CI 60.3–67.6) to 74.6 (95% CI 69.3–80.0).
The difference at twelve months between the two groups
is 9.4 (95% CI 2.4–16.4). (Fig. 3).
KSS function
The study group showed improved function at six
weeks, as measured with the KSS functional measure-
ment, with further improvements at 12, 24 and 52 weeks.
The study group improved from 67.0 (95% CI 64.0–70.1)
to 78.6 (95% CI 74.7–82.5) at 52 weeks, with a difference
of 10.6 (95% CI 4.1–17.1). The control group showed
slight improvement from 67.1 (95% CI 64.0–70.3) to
70.8 (95% CI 66.2–75.3) with the difference between the
groups 7.8 (1.9–13.8) (Fig. 4).
KOOS
The adjusted mean values of the KOOS are listed in
Table 2.
KOOS pain On the pain subscale of KOOS, the study
group improved from 61.2 (95% CI 58.7–63.7) to 68.9
(95% 66.0–71.8) at 52 weeks, with a difference of 7.7 where
a difference of 10 is considered a clinically detectable dif-
ference. The control group showed less improvement with
a difference between the groups of 5.2 (p = 0.02). This dif-
ference is not considered clinically important.
KOOS symptoms The study group improved from 64.5
(95% CI 61.8–67.2) to 72.4 (95% CI 74.7–82.5) whereas
the control group shows hardly any improvement from
baseline. The difference at 52 weeks from baseline for
the study group is 7.9 which is slightly less than 10, the
clinically detectable cut off mark traditionally used in
KOOS scores.
KOOS activities of daily living The sub score for ADL
shows an increase in the study group from 65.3 (95% CI
62.9–67.7) to 75.2 (95% CI 72.4–78.0) and a difference
of 9.8 (p < 0.001) while the control group shows no sta-
tistically significant difference from baseline.
KOOS sports and recreation The sub score for sport
and recreation increased for the study group during the
whole follow-up. The scores for the study group in-
creased from 24.6 (95% CI 21.6–27.6) to 40.2 (95% CI
36.7–43.8) with a difference of 15.7 (p < 0.001). The con-
trol group did not show much improvement during this
time and the difference between the groups at 52 weeks
was 12.5 (p < 0.001), which is both a clinical and statis-
tical significant difference.
KOOS quality of life The sub score for quality of life
did not show much change for either group, the study
group increasing from 52.2 (95% CI 49.4–55.0) to 55.7
(95%52.5–59.0) and the control group actually decreas-
ing from 52.3 (95% CI 49.5–55.1) to 49.5 (95% CI 45.4–
53.6). The difference between the groups at 52 weeks
was 6.1 (p = 0.02) which is not a clinically detectable
difference.
Discussions
This exploratory study indicates that pain and function
(activity of daily living and sports and recreation) can be
improved in comparison to placebo during one-year use
of the Unloader brace. The study showed some improve-
ments in primary endpoints except in the KOOS
Table 1 Baseline demographic and clinical characteristics
Baseline characteristics Study Group Control Group
Participants 74 75
Age, in years (mean, SD) 59.6 (8.0) 60.3 (6.9)
Female gender 27 (37%) 33 (44%)
BMI (mean, SD) 27.5 (3.0) 26 (3.0)
KOOS Pain (mean, 95% CI) 61.2 (58.7–63.7) 61.1 (58.7–63.6)
KOOS Symtom (mean, 95% CI) 64.6 (61.8–67.2) 64.4 (61.7–67.1)
KOOS ADL (mean, 95% CI) 65.3 (62.9–67.7) 65.1 (62.7–67.5)
KOOS Sport/Rec (mean, 95% CI) 14.6 (21.6–27.6) 25.0 (22.0–28.0)
KOOS QoL (mean, 95% CI) 52.2 (49.4–55.0) 52.3 (49.5–55.1)
KSS Score (mean, 95% CI) 64.3 (60.3–67.6) 64.0 (60.3–67.6)
KSS Function (mean, 95% CI) 67.0 (64.0–70.1) 67.1 (64.0–70.3)
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subgroup measuring quality of life at one year follow up.
The differences between the groups at 6, 12 and
24 weeks are hard to interpret due to poor return at
these intervals. Most patients showed up at some of the
follow up appointments i.e. either at six weeks or three
months but not both, and some showed up at all ap-
pointments. Some subjects stated that they did not have
time for all the follow-up visits. Some patients choose
not to come to the appointment but sent in the
self-administered questionnaires, and others showed up
at the appointments but neglected to send in the
self-reported questionnaires.
There were more dropouts from the control group
than the study group, mostly due to mechanical issues,
such as the brace sliding of the leg or hurting the
patient.
It is interesting to note that improvements in KSS
score are not evident at the six week follow up and the
difference between groups does not become apparent
until after six months suggesting that long term follow
up is needed to see the difference. Many studies are lim-
ited by short follow up times. This also suggests that it
may take time for the patients to adjust to the brace in
the clinical setting and full results should not be ex-
pected immediately.
The high dropout rate in the control group compared
to the study group shows in our opinion that the design
of the brace matters and supports the theory that
Fig. 3 Predictive margins of KSS with 95% CI at baseline 6,12,24 and 52 weeks
Fig. 4 Predictive margins of KSS Function with 95% CI at 6,12,24 and 52 weeks
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unloading the affected compartment can relief pain and
improve function. With this said, it should be kept in
mind that the placebo braces might still have clinical ef-
fect as shown in biomechanical studies even though the
dynamic tension strap has been removed. This effect
might be due to diminished muscular co contractions
rather than compartmental unloading as suggested by
Ramsey et al. [16].
The KSS questions for pain and function ask patients
to remember their experience the previous four weeks
and the KOOS questionnaire the previous week. It is a
thought for mind if these kinds of outcome scores are
appropriate for measuring outcomes for a device that is
only used during activity rather than continuous pain re-
lieving effect such as medication or operations. This
might explain larger differences between groups in func-
tional scores rather than pain and symptom scores.
There is a clinically and statistically significant improve-
ment in KSS and KSS function for both groups at one year
compared with baseline. These results are compatible with
previously published studies [17, 18]. There is also differ-
ence between groups but it is not statistically significant.
For KOOS Pain, symptoms and quality of life there is a
slight improvement at one year compared with the base-
line for the control group even though it’s questionable
that this improvement is clinically significant. There is
both a clinical and statistical significant improvement in
the category of sport and recreation in the study group,
with significant difference between the groups at one year
follow up.
In the study protocol we had set the economic aspects
of brace use as the secondary endpoint. This proved to
be more complex than we anticipated and beyond the
scope of this article and therefore the secondary end-
point was limited to the dropout rate.
Conclusions
The results of this study reflect our experience in clinical
practice, there are many who find braces useful and there
are those who don’t think that they add anything to their
treatment. Further research should be focused on identify-
ing the responders and non-responders of this treatment
applying OARSI criteria [19] for responders and to see
what if any differentiates these groups.
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